drug: haloperidol |
|
|
| Clinical class | antipsychotic, neuroleptic |
| Action | dopamine antagonist |
| Chemical class | butyrophenone |
| CSA schedule | none |
| DEA number | none |
| Routes of administration | oral, parenteral (including depot) |
| Associated with (substance-related)
|
disorders: none |
| Availability | prescription |
U.S. Preparations:
- Haloperidol Decanoate Injection (Apotex)
- Haldol® Decanoate 50 Injection, Haldol® Injection, Tablets and Concentrate (Ortho-McNeil) FDA approved indications: psychotic disorders, Tourette's disorder, severe behavior problems in children
| Dose: | 0.5 mg. | 1.5 mg. | 5 mg. | ||||||
| Color: | light green body - dark green cap | white | white | ||||||
| Shape: | round | round | |||||||
| Type: | capsule | scored tablet | scored tablet | ||||||
| Imprint: | "Searle" | "Searle 41" | "Searle 12" | ||||||
Preparations Outside U.S.:
- Alased, Aloperidin, Apo-Haloperidol, Avant, Bioperidolo, Buteridol, Cereen, Dozic, Duraperidol, Fortunan, Haloneural, Haloper, Haloperin, Novo-Peridol, Peridol, Serenace, Serenelfi, Sevium, Sigaperidol, Sylador, Zafrionil
- (combination with buzepide): Vesadol
- (combination with isopropamide): Vesalium